Psychiatric NP Scope of Practice for Weight Loss/GLP-1 in Georgia

You’re a psychiatrist or PMHNP watching patients gain 40 pounds on antipsychotics, or you’re seeing the overlap between binge eating disorder and obesity — and you’re wondering: Can I legally prescribe semaglutide or phentermine via telehealth? The short answer: Maybe. It depends on your state, your credentials, whether the medication is controlled, and how you structure the patient encounter.

Here’s the reality: federal telehealth rules for controlled substances are in flux (extended through 2026 but awaiting permanent regs), state laws vary wildly (New York demands an in-person visit for controlled meds; Florida doesn’t), and scope-of-practice questions loom large for PMHNPs treating metabolic conditions outside traditional mental health. Add in state-specific obesity prescribing standards — like Florida’s mandatory quarterly follow-ups or New Jersey’s psych evaluation requirement — and you’re navigating a minefield.

This guide breaks down what you actually need to know: the current DEA telemedicine extension, which states allow telehealth prescribing of weight-loss drugs (controlled and non-controlled), whether psychiatrists and psych NPs can legally treat obesity, and the practical compliance steps (PDMP checks, informed consent, documentation) to avoid trouble. We’ll cover California, Texas, Florida, New York, Pennsylvania, and Illinois in detail — the states where most telehealth weight-loss action is happening.

The Federal Landscape: DEA Rules for Telehealth Prescribing of Controlled Substances

The Ryan Haight Act and COVID-Era Flexibilities

Normally, federal law (the Ryan Haight Online Pharmacy Consumer Protection Act of 2008) requires an in-person medical evaluation before a practitioner can prescribe Schedule II–V controlled substances via telemedicine to a new patient. There are narrow exceptions (like a provider covering for a colleague who saw the patient in person), but the baseline rule was: no face-to-face visit, no controlled prescription.

During COVID-19, the DEA waived this requirement under public health emergency authority. Psychiatrists could suddenly prescribe Adderall or Ritalin via video to new ADHD patients they’d never met in person. Weight-loss docs could write phentermine (Schedule IV) prescriptions after a telehealth visit. This was supposed to be temporary.

The 2026 Extension — Kicking the Can Down the Road

As of January 2, 2026, the DEA and HHS announced a fourth extension of these telehealth flexibilities through December 31, 2026. Translation: you can still prescribe controlled substances via telemedicine nationwide without an initial in-person exam, but only until the end of 2026. The government explicitly said this extension prevents a ‘telehealth cliff’ while they finalize permanent rules.

What this means for you right now:

• Federally legal to prescribe phentermine (Schedule IV appetite suppressant) via telehealth to a new patient — if your state allows it and you meet standard-of-care requirements.
• Federally legal to prescribe stimulants (Adderall, Vyvanse) for ADHD via telehealth — again, if state law permits and it’s clinically appropriate.
• You still need a DEA registration and must comply with all other federal rules (no prescribing to patients you know are diverting, proper record-keeping, etc.).

What’s coming: The DEA is working on permanent telemedicine regulations. Proposed rules from January 2025 suggest they may create a ‘Special Registration for Telemedicine’ pathway allowing providers to prescribe Schedule III–V controlled substances to patients they’ve never seen in person, and possibly allow Schedule II prescribing by certain specialists (like psychiatrists for ADHD meds) under restrictions. Public comment periods are open. Until final rules drop, expect the extension to remain in place — but don’t assume it lasts forever. Plan your practice with an exit strategy (like offering in-person visits or hybrid models) for when federal rules tighten.

GLP-1 Agonists Aren’t Controlled — Simpler Path

Importantly, the newer weight-loss medications everyone’s talking about — semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) — are not controlled substances. They’re FDA-approved GLP-1 receptor agonists with no DEA schedule. That means the Ryan Haight Act doesn’t apply. You can prescribe these via telehealth nationwide without worrying about the DEA’s in-person exam rule at all. The only constraints are state telehealth laws and standard prescribing guidelines (ensure the patient meets BMI criteria, document contraindications, monitor side effects, etc.).

Bottom line: If you’re prescribing GLP-1s for weight loss via telehealth, your main concern is state law and medical board expectations, not DEA rules. If you’re prescribing phentermine or other controlled appetite suppressants, you’re operating under the federal extension through 2026 — but state rules can be stricter.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Can Psychiatrists Legally Prescribe Weight-Loss Medications? Scope of Practice Realities

Physicians (MD/DO Psychiatrists): Broad Authority, Clinical Responsibility

As a board-certified psychiatrist (or even a general practice MD), you have unrestricted prescribing authority in your state. There’s no special ‘obesity license.’ You can legally prescribe semaglutide, phentermine, or any FDA-approved weight-loss drug — assuming you’re competent to do so and follow the standard of care.

Many psychiatrists already prescribe metformin off-label to counteract antipsychotic-induced weight gain, or bupropion (Wellbutrin) which has some weight-loss effects. Managing obesity in patients with serious mental illness is increasingly recognized as part of integrated care. You’re not stepping outside your scope by treating a metabolic comorbidity in a psych patient.

However: Medical boards will hold you to the same standards as any physician treating obesity. That means:

• Documenting BMI ≥30 (or ≥27 with comorbidities like hypertension or diabetes) to justify prescribing.
• Obtaining informed consent about risks and benefits (especially for medications with systemic effects like phentermine’s cardiovascular risks or GLP-1s’ GI side effects).
• Monitoring appropriately: e.g., checking blood pressure if prescribing a stimulant-like drug, monitoring blood sugar if using GLP-1s in diabetic patients, scheduling periodic follow-ups (many states and guidelines recommend monthly or quarterly).
• Counseling on lifestyle: prescribing a drug alone without diet/exercise guidance doesn’t meet the standard of care for obesity treatment.

In states like Florida, explicit rules apply to all physicians prescribing obesity meds: you must document the patient’s obesity (BMI or body fat percentage), obtain written informed consent outlining the risks of the drugs and alternatives, and re-evaluate the patient at least every 3 months while they’re on anti-obesity medications. A psychiatrist prescribing Wegovy in Florida must follow these rules just like an endocrinologist would.

Practical reality: Most psychiatrists don’t have formal obesity medicine training. If you want to do this at scale (open a weight-loss telehealth practice), consider:

• Getting certified by the American Board of Obesity Medicine (ABOM) or completing CME in obesity pharmacotherapy to bolster credibility and knowledge.
• Collaborating with primary care or endocrinology for complex cases (e.g., a patient with poorly controlled diabetes and depression — you manage psychiatric meds, they manage metabolic optimization, and you coordinate GLP-1 use).
• Being transparent about your role: if you’re primarily treating a patient’s depression and also addressing antipsychotic-induced weight gain with metformin or a GLP-1, document that integrated rationale clearly.

PMHNPs and Psychiatric NPs: Tread Carefully on Scope

For Psychiatric-Mental Health Nurse Practitioners (PMHNPs), scope of practice is defined by your training and certification, not just your license. A PMHNP is educated to diagnose and treat mental health conditions. Prescribing purely for obesity (a metabolic/endocrine condition) might be viewed by state nursing boards as outside your scope unless you have additional credentials or physician oversight.

State-by-state variation:

• Texas/Florida: NPs must practice under physician protocols or supervision (Texas requires a Prescriptive Authority Agreement; Florida requires collaboration unless you have autonomous practice status). If you’re a PMHNP in Texas wanting to prescribe phentermine for weight loss, your collaborating physician should ideally be someone with obesity medicine expertise (family practice, internal medicine), not just another psychiatrist. The protocol should explicitly cover weight-loss prescribing and include the scope (what drugs, for which patients, monitoring frequency).
• California: NPs operate under Standardized Procedures with physician oversight, but experienced NPs can now achieve independent practice under AB 890 (phased in 2023–2026). Even with independent practice, a PMHNP treating obesity is venturing outside their certified specialty — you’d be wise to get additional training (obesity pharmacotherapy courses) and possibly consult with a physician for complex cases. California’s nursing board expects NPs to practice within their competence.
• New York: NPs can practice independently after 3,600 hours of collaboration. A PMHNP with independent practice could legally prescribe weight-loss meds, but if it’s not within mental health scope, you risk professional scrutiny. If you’re addressing binge eating disorder and prescribing a GLP-1 as part of that treatment, you’re on stronger ground (it’s a psychiatric comorbidity). If you’re running a pure ‘med spa’ weight-loss clinic, you’re asking for trouble.
• Pennsylvania/Illinois: Require collaborative agreements (PA) or offer Full Practice Authority after 4,000 hours (IL). Same principle: a PMHNP should either limit prescribing to mental health overlap (like treating binge eating or depression contributing to obesity) or work under a physician’s delegation/protocol that covers metabolic treatment.

Bottom line for PMHNPs: You can prescribe weight-loss medications if your state allows NPs to prescribe them and you have physician oversight or independent practice authority — but you should stay within your training or get additional credentials. Many psych NPs avoid this liability by referring patients to primary care or a dedicated weight-loss clinic rather than managing it themselves.

State-by-State Breakdown: Telehealth Prescribing Rules for Weight Loss Drugs

California: Telehealth-Friendly, but Watch Corporate Practice and PDMP Rules

Key Rules:

• No in-person exam required for telehealth prescribing (California law allows a proper telehealth encounter to satisfy the ‘appropriate prior examination’ requirement). You can prescribe GLP-1s or phentermine after a video visit.
• Telehealth consent mandatory: Business & Professions Code §2290.5 requires you to obtain and document the patient’s consent to receive care via telehealth. This can be verbal or written but must be in the record.
• PDMP (CURES) checks: Before prescribing any Schedule II–IV controlled substance (e.g., phentermine), you must query California’s CURES database at the first prescription and then at least every 4 months for ongoing therapy. Document these checks in the patient chart.
• E-prescribing required: All prescriptions (including controlled) must be sent electronically as of 2022.
• Corporate Practice of Medicine (CPOM): California has a strict CPOM doctrine — only physicians or physician-owned professional corporations can employ physicians or control medical decision-making. If you’re working with a telehealth platform, ensure it’s structured legally (e.g., the platform is a management service organization providing admin support, and physicians retain clinical autonomy). Non-physician-owned weight-loss clinics are illegal in CA unless properly structured.
• Advertising restrictions: CA B&P §651 prohibits misleading health claims. Don’t advertise ‘guaranteed weight loss’ or use physician titles for non-MDs (like calling an NP ‘Dr.’ in marketing without clarifying credentials).

Insurance note: California’s Medi-Cal (Medicaid) will stop covering GLP-1 medications for weight loss as of January 2026, classifying them as non-covered/cosmetic. Commercial insurers in CA still vary (some cover with prior auth), but many patients will be cash-pay. Telehealth providers should be transparent about costs.

NP/PA scope: California NPs need Standardized Procedures (physician oversight) unless they qualify for AB 890 independent practice (effective fully in 2026 for experienced NPs). Even independent NPs should have additional training if treating obesity outside their specialty focus. PAs need a practice agreement with a physician; no ratio requirement as of 2019 (SB 697), but collaboration must be documented.

Compliance checklist:

• Verify patient location in California and confirm you’re CA-licensed.
• Obtain telehealth consent at first visit.
• Check CURES before prescribing phentermine (first time and every 4 months).
• Document BMI, comorbidities, informed consent, diet/exercise counseling.
• Schedule follow-ups monthly or quarterly (align with standard obesity treatment guidelines).
• Use HIPAA-compliant video platform and e-prescribe all meds.

Texas: Telemedicine-Friendly, but NPs Need Physician Oversight

Key Rules:

• Telehealth allowed for establishing a patient relationship via live video or store-and-forward plus audio (Texas Occ. Code §111.005). No state-mandated in-person visit for prescribing weight-loss meds.
• Standard of care required: Your telehealth encounter must be sufficient to meet the same standard you’d use in person (document history, exam findings, clinical justification).
• PDMP (Tx PMP AWARxE): Texas law requires checking the PMP before prescribing opioids, benzos, barbiturates, or carisoprodol. Phentermine isn’t on the mandatory list, but best practice is to check it for any controlled substance to identify potential drug interactions or abuse history.
• Follow-up and coordination: Texas Occ. Code §111.007 requires telehealth providers to give patients follow-up care instructions and, with patient consent, send a report to the patient’s primary care provider within 72 hours of the telehealth visit. This ensures continuity of care.
• NP/PA scope: Texas NPs and PAs must have a Prescriptive Authority Agreement (PAA) or delegation agreement with a Texas-licensed physician to prescribe any medications. The PAA must list weight-loss drugs if you’re prescribing them. NPs can prescribe Schedule III–V controlled substances (like phentermine) under delegation; they cannot prescribe Schedule II (like Adderall) except in hospital/hospice settings. PAs can prescribe Schedule II–V if delegated.
• Corporate practice: Texas also prohibits corporate practice of medicine. Weight-loss clinics must be physician-owned or use compliant structures.

Controlled substance note: Under the federal DEA extension, you can prescribe phentermine via telehealth in Texas through 2026. When that expires, Texas has no state in-person rule, so unless DEA reinstates one, you’d still be able to do telehealth prescribing as long as you meet standard of care.

Compliance checklist:

• Confirm patient is in Texas and you hold a TX medical license.
• Conduct live video visit (store-and-forward alone isn’t sufficient for new patients needing prescriptions).
• Document encounter thoroughly (weight, BMI, vital signs if obtainable, history, clinical impression).
• Check TX PMP for controlled substances (phentermine) and document.
• E-prescribe (Texas encourages but doesn’t strictly mandate e-prescribing; however, many pharmacies now require it for controlled substances).
• Send follow-up plan to patient and notify their PCP (with consent) within 72 hours.
• If you’re an NP/PA, ensure your PAA covers weight-loss prescribing and your supervising physician is available for consultation.

Florida: Permissive for Telehealth, but Strict Obesity Treatment Standards

Key Rules:

• Telehealth prescribing allowed: Florida Statute §456.47 allows telehealth to establish a patient relationship without an in-person visit for most services. However, Florida bans prescribing Schedule II controlled substances via telehealth (except for psychiatric treatment, inpatient care, hospice, or nursing home patients). Good news for weight loss: phentermine is Schedule IV, so it’s permitted via telehealth. GLP-1s (not controlled) are also permitted.
• Obesity prescribing standards (Florida Admin. Code 64B8-9.012): Every physician prescribing weight-loss drugs must:
• Document BMI ≥30 (or ≥27 with comorbidities, or body fat >25% male/>30% female).
• Perform an initial evaluation (in-person or via telehealth) including history, physical exam, and any necessary diagnostic tests (labs, EKG if indicated).
• Obtain written informed consent from the patient outlining the risks and benefits of the medication and alternatives.
• Re-evaluate the patient at least every 3 months while on anti-obesity medication (can be via telehealth follow-up).
• Not prescribe SSRIs or certain other drugs off-label solely for weight loss (Florida’s rule forbids prescribing drugs for weight loss that aren’t FDA-approved for that indication).
• Consumer protections: Florida’s Commercial Weight-Loss Practices Act requires weight-loss providers to give clients a written price quote, disclose program duration, and provide a ‘Weight-Loss Consumer Bill of Rights’ (a state-mandated form outlining client rights). This applies to weight-loss programs, not just individual prescriptions, but if you’re running a structured telehealth program (monthly subscriptions, etc.), you should comply.
• PDMP (E-FORCSE): Florida requires checking the E-FORCSE database before prescribing any controlled substance to a patient age 16+ (with narrow exceptions). Document the query.
• NP/PA scope: Florida APRNs need physician supervision unless they qualify for autonomous practice (available for family/adult NPs with experience, but not yet for PMHNPs as of 2025). Even autonomous NPs should ensure they’re practicing within their training. PAs need supervising physician agreements. All advanced practitioners must follow the same obesity prescribing standards as physicians.

Psychiatric exception: Florida explicitly allows telehealth prescribing of Schedule II controlled substances for psychiatric disorders. So a Florida psychiatrist can prescribe Adderall for ADHD via telehealth legally (it’s an exception to the Schedule II ban). But prescribing phentermine for obesity isn’t a psychiatric disorder, so that doesn’t fall under the exception (luckily phentermine is Schedule IV, so no issue).

Compliance checklist:

• Verify patient in Florida; ensure FL licensure.
• Conduct telehealth visit (video preferred to visually assess patient and build rapport).
• Document BMI, medical history, exam (even if remote — e.g., patient self-reports weight/height, you visually assess general appearance, discuss symptoms).
• Obtain written informed consent (Florida requires it in writing for obesity meds — can be electronic signature).
• Check E-FORCSE PDMP if prescribing phentermine (or any controlled substance).
• Schedule follow-up within 3 months (Florida’s rule — set up quarterly check-ins at minimum).
• Provide the ‘Weight-Loss Consumer Bill of Rights’ if running a program (downloadable from Florida Dept. of Health).
• Avoid off-label prescribing of non-approved drugs for weight loss (stick to FDA-approved: phentermine, semaglutide, tirzepatide, liraglutide, etc.).

New York: Strict In-Person Rule for Controlled Substances

Key Rules:

• In-person exam required for controlled substances: New York’s Department of Health regulation (10 NYCRR §80.63) states that no controlled substance shall be prescribed prior to an in-person medical evaluation of the patient by the prescribing practitioner, with limited exceptions. This rule was reinstated/clarified in May 2025 after the COVID public health emergency ended.
• Exceptions: You can prescribe a controlled substance via telehealth in NY only if:
• Another NY-licensed provider performed an in-person exam of the patient within the last 12 months and shared that information with you (consulting provider scenario).
• You are covering for a colleague who saw the patient in person (on-call/backup scenario).
• It’s an emergency and you have an existing patient relationship, in which case you can prescribe a maximum 5-day supply of a controlled substance.
• Practical impact: If you want to prescribe phentermine (Schedule IV) for weight loss to a new patient in New York, you (or a collaborating provider) must see them in person first. Many telehealth weight-loss companies operating in NY partner with local clinics to do an initial in-person visit, then continue care via telemedicine. Alternatively, some avoid controlled substances entirely and only prescribe GLP-1s (not controlled) via telehealth in NY.
• GLP-1s and non-controlled meds: For semaglutide, tirzepatide, or any non-controlled weight-loss drug, no in-person requirement exists in NY. You can prescribe these via telehealth after an appropriate evaluation (live video is standard; audio-only is permitted in some mental health contexts but not ideal for obesity treatment where you should visually assess the patient).
• PDMP (I-STOP): New York requires checking the PMP registry no more than 24 hours before prescribing any Schedule II, III, or IV controlled substance, and you must document the check. This is one of the strictest PDMP requirements in the country — every controlled prescription (including refills) needs a PMP check within 24 hours prior.
• E-prescribing mandatory: New York mandates electronic prescribing for all medications (controlled and non-controlled). Paper prescriptions are only allowed in very limited circumstances (system downtime, patient in nursing home without e-prescribe access, etc.).
• NP/PA scope: New York NPs can practice independently after 3,600 hours of collaboration with a physician (NP Modernization Act). An experienced family NP could run a weight-loss practice independently. A PMHNP with independent practice could legally prescribe weight-loss meds, but it’s professionally risky if obesity treatment is outside their usual mental health focus — boards expect competence. PAs need supervising physician agreements to prescribe.

Compliance checklist (if prescribing controlled substances like phentermine in NY):

• Arrange an in-person exam (either you see the patient, or a collaborating NY provider does and shares records) before prescribing any controlled weight-loss med.
• Check NY PMP within 24 hours before each prescription (including refills) and document.
• E-prescribe all medications.
• Maintain thorough documentation (weight, BMI, diet history, contraindications, informed consent).
• If you’re only prescribing GLP-1s (non-controlled), you can skip the in-person requirement — just do a proper telehealth evaluation (video, document findings).

Alternative approach: Many NY telehealth providers stick to GLP-1s only to avoid the in-person hurdle. Semaglutide and tirzepatide are highly effective and not controlled, so you can offer a compliant telehealth program focused on those agents and refer patients needing phentermine to their PCP or a local clinic.

Pennsylvania: Flexible Telehealth, but PDMP Vigilance Required

Key Rules:

• No comprehensive telehealth statute: Pennsylvania doesn’t have a single law codifying telehealth like other states, but the State Board of Medicine has guidance allowing telehealth as long as you meet the standard of care. Basically, if you can obtain enough information via telemedicine to make a sound clinical decision (equivalent to what you’d get in person), you can prescribe.
• Controlled substances: Pennsylvania has no state law banning telehealth prescribing of controlled substances. Under the federal DEA extension, you can prescribe phentermine or stimulants via telehealth in PA through 2026. PA defers to federal rules plus expects you to follow professional standards.
• PDMP (PA PMP): Pennsylvania law (Act 126 of 2016) requires prescribers to check the PA Prescription Drug Monitoring Program before issuing:
• Any opioid or benzodiazepine prescription to a new patient.
• Every subsequent opioid or benzo prescription (refills included).For other controlled substances (like phentermine or stimulants), the law recommends checking the PDMP but doesn’t mandate it for every prescription. Best practice: check it before prescribing phentermine the first time and periodically thereafter.
• E-prescribing: Federal Medicare rules and state guidance encourage e-prescribing; as of 2023, controlled substances should be e-prescribed when possible (EPCS — Electronic Prescribing for Controlled Substances).
• NP/PA scope: Pennsylvania CRNPs (nurse practitioners) must have a Collaborative Agreement with a physician to prescribe. They can prescribe Schedule II–V controlled substances if delegated (Schedule II limited to 30-day supply initially). No independent practice in PA yet. PAs similarly need supervising physician agreements. A PMHNP in PA wanting to prescribe weight-loss meds should ideally have a collaborating family practice or internal medicine physician (not just a psychiatrist) to cover the metabolic aspects.
• Obesity treatment standards: Pennsylvania has no specific state rules for obesity prescribing (unlike Florida). You follow general medical standards: document BMI, assess for secondary causes (thyroid, etc.), discuss lifestyle changes, obtain consent, monitor side effects. The state medical board would compare your practice to national guidelines (NIH, Endocrine Society, etc.) if a complaint arises.

Compliance checklist:

• Verify patient is in PA and you’re PA-licensed.
• Conduct telehealth visit via video (recommended for initial visit to assess patient and build relationship).
• Document encounter thoroughly.
• Check PA PMP before prescribing phentermine or any controlled substance (document query and results).
• E-prescribe all controlled substances via EPCS system.
• Follow up appropriately (monthly or quarterly depending on the drug and patient stability).
• If you’re an NP/PA, ensure your collaborative agreement covers weight-loss prescribing.

Local tip: Pennsylvania has many rural areas with limited access to specialists. Telehealth for weight management is welcomed here — just maintain high standards and coordination with primary care to avoid regulatory scrutiny.

Illinois: Telehealth-Friendly with Full Practice Authority for NPs

Key Rules:

• Telehealth explicitly allowed: Illinois Telehealth Act permits establishing a patient relationship via telehealth with no in-person requirement. You can prescribe medications (including controlled substances, under current federal allowance) after a proper telehealth encounter.
• Audio-only permitted: Illinois allows audio-only telehealth in some cases (for patients who can’t do video), though for weight-loss treatment a video visit is recommended to visually assess the patient and discuss injection technique for GLP-1s.
• Controlled substances: Illinois has no state ban on telehealth prescribing of controlled substances. Under the DEA extension, you can prescribe phentermine via telehealth in IL through 2026. IL follows federal rules.
• PDMP (PMPnow): Illinois requires checking the Prescription Monitoring Program each time you prescribe a Schedule II narcotic (opioid) and at least every 90 days for patients on continuous opioid therapy. For non-narcotic controlled substances (stimulants, phentermine), checking is encouraged but not mandated by law. Most providers check it anyway for liability protection.
• E-prescribing: Illinois requires e-prescribing for all controlled substances as of January 2023 (via EPCS).
• NP/PA scope: Illinois offers Full Practice Authority (FPA) for APRNs after 4,000 hours of experience and additional training. An NP with FPA can practice and prescribe independently, including Schedule II–V controlled substances (with a consultation agreement for Schedule II opioids). A family NP with FPA could run an independent weight-loss telehealth practice. A PMHNP with FPA could legally do the same, but should consider whether treating obesity is within their competence (additional training advised). PAs can prescribe under physician delegation; IL has flexible collaboration rules (no chart co-sign mandates post-2018 PA Modernization).
• Obesity treatment standards: Illinois has no specific state rules; standard medical practice applies. Follow national guidelines (document BMI, assess comorbidities, provide lifestyle counseling, monitor adverse effects).

Insurance note: Illinois Medicaid started covering prescription weight-loss medications (like Wegovy) in 2024 for qualifying patients. Commercial payers vary. Telehealth parity laws in IL mean insurers must cover telehealth visits at the same rate as in-person, which helps with reimbursement.

Compliance checklist:

• Verify patient in Illinois; ensure IL licensure.
• Conduct telehealth visit (video preferred).
• Document encounter (weight, BMI, history, plan).
• Check IL PMPnow if prescribing controlled substances (especially phentermine — recommended before first prescription).
• E-prescribe all controlled meds.
• Obtain patient consent for telehealth (required by IL law — document it).
• Schedule appropriate follow-up (monthly or quarterly based on medication and guidelines).
• If you’re an NP/PA, ensure you have FPA or a collaborative agreement covering weight-loss prescribing.

Local tip: Illinois (especially Chicago area) has a competitive market for weight-loss services, including hospital-based programs. Telehealth providers can differentiate by offering convenience, flexible scheduling, and coordinated care with mental health (since many obesity patients have comorbid depression or binge eating).

Practical Compliance Steps: What Every Telehealth Weight-Loss Prescriber Should Do

Regardless of your state or provider type, here are the universal best practices to stay compliant and safe:

1. Verify Patient Location and Your Licensure

You must be licensed in the state where the patient is physically located at the time of the visit. No exceptions (unless you’re in a federal system like VA). Some telehealth platforms auto-detect location via IP or ask the patient to confirm; document this in your note. If you practice in multiple states, maintain active licenses and be aware of each state’s rules.

2. Conduct a Proper Telehealth Evaluation

State boards and malpractice insurers will scrutinize whether your telehealth encounter met the standard of care. For weight-loss treatment, that means:

• Comprehensive history: Current weight, weight history, diet/exercise attempts, medical conditions (diabetes, hypertension, thyroid, etc.), medications (check for drug interactions), psych history (depression, eating disorders), family history of obesity or metabolic disease.
• Assessment of eligibility: BMI ≥30 or ≥27 with comorbidities (FDA criteria for most weight-loss drugs). Document BMI calculation in your note.
• Physical exam (as feasible via telehealth): Visual assessment of general appearance, discussion of vital signs (patient can self-report weight/height; some use home BP cuffs or digital scales). For GLP-1s, discuss any GI symptoms. For phentermine, ask about cardiovascular symptoms (chest pain, palpitations).
• Lab review: Many guidelines recommend baseline labs before starting weight-loss meds (fasting glucose, lipid panel, liver/kidney function, TSH if indicated). You can order these via telehealth and review results before prescribing. Some states (like New Jersey) explicitly require lab work for obesity treatment.
• Informed consent: Explain the medication’s mechanism, benefits, risks (side effects, contraindications), alternatives (diet/exercise, other meds, surgery), and expected outcomes. Document this discussion. In Florida and some other states, written informed consent is mandatory — use an electronic consent form.

3. Check State PDMP Before Prescribing Controlled Substances

If you’re prescribing phentermine or any controlled medication, query the state’s Prescription Drug Monitoring Program. Document:

• Date and time of query.
• Results (e.g., ‘No concerning findings; no other controlled substances in last 12 months’ or ‘Patient is on lorazepam from another provider; discussed overlap and confirmed appropriate use’).
• States have different mandates (New York: within 24 hours before each Rx; California: first Rx and every 4 months; Pennsylvania: before each opioid/benzo). Follow your state’s specific rule, but when in doubt, check it every time for controlled weight-loss meds.

4. E-Prescribe All Medications

Most states now require or strongly encourage electronic prescribing, especially for controlled substances (EPCS). Benefits: reduces fraud, improves accuracy, meets compliance. Use a certified e-prescribing platform integrated with your EHR. Document if you can’t e-prescribe for some reason (system down, pharmacy doesn’t accept e-scripts) and use an alternative legally allowed method.

5. Document Everything

Your telehealth note should be as thorough as an in-person visit note. Include:

• Patient location (state and city).
• Telehealth modality (video, audio + store-and-forward, etc.).
• Chief complaint and history.
• Examination findings (even if limited — e.g., ‘Patient appears well, appropriate affect, no distress evident on video’).
• Assessment (diagnosis: Obesity, BMI 34, with hypertension; or Binge Eating Disorder with comorbid obesity).
• Plan (medication prescribed, dosing, duration, follow-up schedule, lifestyle counseling provided).
• Informed consent discussion.
• PDMP check (if applicable).
• Any coordination with other providers (e.g., ‘Discussed with patient’s PCP Dr. Smith; will send summary’).

6

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated